SCHEMBL22491481

SCHEMBL22491481

COC(=O)c1cc2c(c(OC)c1)CCC(=O)N2

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CRBN Q96SW2 2/20 0.48
▸ TUBB4A P04350 1/20 0.47
▸ TUBB P07437 1/20 0.47
▸ TUBA3C P0DPH7 1/20 0.47
▸ TUBA1B P68363 1/20 0.47
▸ TUBA4A P68366 1/20 0.47
▸ TUBB4B P68371 1/20 0.47
▸ TUBB3 Q13509 1/20 0.47
▸ TUBB2A Q13885 1/20 0.47
▸ TUBB8 Q3ZCM7 1/20 0.47
▸ TUBA3E Q6PEY2 1/20 0.47
▸ TUBA1A Q71U36 1/20 0.47
▸ TUBA1C Q9BQE3 1/20 0.47
▸ TUBB6 Q9BUF5 1/20 0.47
▸ TUBB2B Q9BVA1 1/20 0.47
▸ TUBB1 Q9H4B7 1/20 0.47
▸ ALDH1A1 P00352 4/20 0.46
▸ LMNA P02545 1/20 0.46
▸ ALOX15 P16050 1/20 0.46
▸ HTT P42858 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29734435 1.00 CRBN (0.48) CRBNTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL22491426 0.87 CA12 (0.47) CRBNTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL22491512 0.84 CRBN (0.43) CRBNTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL22491528 0.84 CRBN (0.49) CRBNTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL29734620 0.84 CRBN (0.49) CRBNTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL3582334 0.79 MAPT (0.42) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL18031229 0.77 CRBN (0.48) CRBNTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL17543332 0.76 PKM (0.39) ALDH1A1MAPK1KDM4EHPGDNR3C1
SCHEMBL28459022 0.74 LMNA (0.48) CRBNTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL29754229 0.74 CRBN (0.64) CRBNTUBB4ATUBBTUBA3CTUBA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11420961-B2 Heterocyclic compounds HOFFMANN-LA ROCHE INC. (US) 2022-08-23 — — US disclosed
EP-3717477-B1 NEW HETEROCYCLIC COMPOUNDS HOFFMANN LA ROCHE (CH) 2022-07-20 — — EP disclosed
US-20200392125-A1 HETEROCYCLIC COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2020-12-17 — — US disclosed
EP-3717477-A1 NEW HETEROCYCLIC COMPOUNDS H. Hoffnabb-La Roche Ag (CH) 2020-10-07 — — EP disclosed
CN-111386269-A Novel heterocyclic compound 豪夫迈·罗氏有限公司 2020-07-07 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11420961-B2 Heterocyclic compounds LPXN, MLX, CCNY CRBN 206/4885TUBB4A 1452/4885TUBB 2352/4885
US-20200392125-A1 HETEROCYCLIC COMPOUNDS LPXN, MLX, CCNY CRBN 206/4885TUBB4A 1452/4885TUBB 2352/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback